about
Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of lifeZoledronic acid in metastatic chondrosarcoma and advanced sacrum chordoma: two case reports.A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.Squamous cell carcinoma of the tongue in a female with advanced breast cancer: A case report of an elderly patient presenting with two types of cancer.Interferon alpha-2b at low doses as long-term antiangiogenic treatment of a metastatic intracranial hemangioendothelioma: a case report.Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR.Role of somatostatin analogs in the management of rare tumors and diseases.Mediastinal images resembling thymus following 131-I treatment for thyroid cancer.Latest developments in targeted therapy for hepatocellular carcinoma.Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial.Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study.Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis.Hemorrhagic peritoneal carcinomatosis treated with a weekly schedule of carboplatin and paclitaxel. A case report.Somatostatin analogs and prednisone in advanced refractory thymic tumors.Ultra-low-dose interleukin-2 in unresectable hepatocellular carcinoma.Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).Once-per-cycle pegfilgrastim in breast cancer patients treated with docetaxel/epidoxorubicin/cyclophosphamide.Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases.Clonal expansion of CD8+ BV8 T lymphocytes in bone marrow characterizes thymoma-associated B lymphopenia.Somatostatin receptor expression in thymic tumors.Thymoma followed by paroxysmal nocturnal hemoglobinuria: a unique clinical association in the context of multiorgan autoimmunity with a potential role for CD8+ T lymphocytes.Management of pain in elderly patients receiving infusion of zoledronic acid for bone metastasis: a single-institution report.Cetuximab is an active treatment of metastatic and chemorefractory thymoma.Thymoma-Associated Immunodeficiency: A Syndrome Characterized by Severe Alterations in NK, T and B-Cells and Progressive Increase in Naïve CD8+ T CellsSomatostatin analogues, a series of tissue transglutaminase inducers, as a new tool for therapy of mesenchimal tumors of the gastrointestinal tractFatal immunodeficiency in a patient with thymoma and Good's syndromeB-cell lymphopenia and hypogammaglobulinemia in thymoma patientsImmunological findings in thymoma and thymoma-related syndromesRole of somatostatin analogue-based therapy in unresponsive malignant thymomasIn vitro and in vivo expression of somatostatin receptors in intermediate and malignant soft tissue tumorsMolecular technology and the recombinant TSH have changed diagnostics of thyroid carcinoma with positive I-131 whole body scan but low serum thyroglobulinThe era of targeted therapies: increasing role for novel oncologic drugs in dermatologyExploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinomaMaintenance Therapy with Biweekly Cetuximab: Optimizing Schedule Can Preserve Activity and Improves Compliance in Advanced Head and Neck CancerBiweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter studyEfficacy and Safety of Cetuximab plus Radiotherapy in Cisplatin-Unfit Elderly Patients with Advanced Squamous Cell Head and Neck Carcinoma: A Retrospective StudyErratum to: A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
P50
Q26741201-CC675C4D-625C-471E-A4B6-823CBC742090Q33270398-CB455D32-C62F-4C13-96BE-8797707E670DQ33273281-61A8A5CD-BC8C-4202-9CF2-B89EA41B8065Q33391296-6BD6765E-A316-4875-8C61-30CF9F492059Q33778427-FC063273-75F6-4D11-8686-54CDF2A8C9F6Q33796738-7E6DD3A8-9C3C-43E6-ABFC-B93068C99743Q35064862-40D3A6BD-B49D-495B-A867-FBB7510B25F3Q35826092-B08B4FA7-7D31-43B7-979B-C656198F8417Q36243205-AE5FFFF3-2F60-4405-80E9-83768C13F84BQ37799829-E926546D-44CB-4FE0-B1A7-9991CB3E72D5Q38282448-7F26B662-DD39-4BFE-91B2-37AD72FA2A94Q38805622-8E3B93D9-3C5C-49D4-882D-42D7C9C07F45Q39311800-E46B1A64-C58B-4D6F-9E07-3DFABF7B3140Q40569299-9272CFA4-4756-44DA-B0F0-B48586D11636Q43937936-D6073427-2F9A-4B51-85D4-78D3302B5492Q44303089-85072C37-CEF4-4F1B-9159-DE0A4139755BQ44813172-6E218459-CE32-40F3-864A-B86A5EA4B776Q45954752-8362EBDB-B21C-42AD-A416-5A97BA8DECE9Q46362575-777D7340-C8C9-481C-BF65-C860A3BA7E4DQ51691630-F6BBA7F0-4231-461D-BEAC-F5F17606E808Q51776402-C88B1B47-3FDE-455D-BD61-8408E8510CD1Q51795936-0A5120AA-6934-4463-B108-4C5DF1C2B5A4Q53180507-8B640B81-C054-4BAD-8C22-76AC97F1B545Q53510879-979C1D79-C1C7-4C0A-A028-878BF63C82C1Q58370821-6A5ACF19-8530-4379-A8AC-62A37CEA1CBBQ60727897-484FAAF0-DC18-4DB9-BF93-3C1A2CD04388Q60953297-FC6EB49F-7B88-475E-B22E-1D09266179DBQ60953332-EE66F5D8-FD0B-4DA9-AC00-BA7D4E2CAF7BQ60953374-0060E034-ED66-46E5-B66B-FB62D43119F4Q73210162-8153F7B3-68B4-480A-BFFA-6A9A0903A0E4Q73742235-C2523A08-96CA-4584-BFC9-13DABCDF950BQ80375929-FFAF0ED1-34BF-4DF0-9025-3244467C7D25Q80495655-2FAA055F-EE24-470D-AECD-C4CE21D60748Q85262602-535015BE-0C02-4BD2-B8B8-1A602AF1BDBFQ91299532-A6FF747D-EDA9-4FCC-86F3-CF8EFC0F4BE1Q91763994-0989BE30-591B-4A50-9CAC-AA52DEA9840AQ93047893-B9F12D25-BFCE-4D9E-AE90-7312AA875272Q93562764-5DCC4262-9950-41AE-98FB-49BEC62FE09E
P50
description
researcher
@en
name
L Montella
@en
L Montella
@nl
type
label
L Montella
@en
L Montella
@nl
prefLabel
L Montella
@en
L Montella
@nl
P106
P31
P496
0000-0002-6397-086X